PSAP

Prosaposin · P07602 · PSAP on Sugi Atlas →

781 patent compounds predicted against PSAP, 689 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fenretinide (SCHEMBL11703)	1.00	1/20
Fenretinide (SCHEMBL11704)	1.00	1/20
Fenretinide (SCHEMBL19121)	1.00	1/20
Fenretinide (SCHEMBL839699)	1.00	1/20
Fenretinide (SCHEMBL4874840)	1.00	1/20
Fenretinide (SCHEMBL4996036)	1.00	1/20
Fenretinide (SCHEMBL9838209)	1.00	1/20
Fenretinide (SCHEMBL10629371)	1.00	1/20
Fenretinide (SCHEMBL13402304)	1.00	1/20
Fenretinide (SCHEMBL15703189)	1.00	1/20
Fenretinide (SCHEMBL17593527)	0.98	1/20
Fenretinide (SCHEMBL17593528)	0.98	1/20
Fenretinide (SCHEMBL17593618)	0.98	1/20
Fenretinide (SCHEMBL17593620)	0.98	1/20
Fenretinide (SCHEMBL17593790)	0.98	1/20
Fenretinide (SCHEMBL17593791)	0.98	1/20
Fenretinide (SCHEMBL17593800)	0.98	1/20
Fenretinide (SCHEMBL17593802)	0.98	1/20
Fenretinide (SCHEMBL14690048)	0.94	1/20
SCHEMBL3850303	0.87	1/20

Clinical trials — most relevant to PSAP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer	PHASE2	COMPLETED
Study of CEP-701 in Treatment of Prostate Cancer	PHASE2	COMPLETED
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients	PHASE2	RECRUITING
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer	PHASE1	COMPLETED
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study	EARLY_PHASE1	WITHDRAWN
Markers for Early Detection of Prostate Cancer	nan	COMPLETED
For Cause Prostate Biopsy in REDUCE Population Trial	nan	COMPLETED
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma	nan	COMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.	nan	COMPLETED
Serum Prostatic Specific Antigen Changes After Bipolar and Monopolar TURP	nan	UNKNOWN
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine	nan	COMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Chemokine Mechanisms in Chronic Pelvic Pain	nan	COMPLETED
Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial	nan	UNKNOWN
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer	nan	COMPLETED
Proteases in Patients With Prostate Cancer That Has Spread to the Bone	nan	COMPLETED
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy	nan	COMPLETED
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15	nan	UNKNOWN
Prostate Active Surveillance Study	nan	RECRUITING
SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity	nan	NOT_YET_RECRUITING
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment	nan	RECRUITING
Biomarkers of Lichen Sclerosus	nan	UNKNOWN
Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation	nan	RECRUITING
SLPI for Prostate Cancer	nan	UNKNOWN
Prospective Evaluation of Proclarix® Test to Improve Risk Stratification in Men Scheduled for MpMRI and Prostate Biopsy in Cantonal Hospital Aarau	nan	RECRUITING
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
To Identify Potential New Urine Markers for the Screening of Prostate Cancer	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PSAP binder may also engage these)

Protein	Name	Similarity
P26779	—	1.000	P26779 →
O13035	—	1.000	O13035 →
P10960	—	0.990	P10960 →
Q61207	—	0.988	Q61207 →
P81405	—	0.961	P81405 →
Q9CXI5	—	0.960	Q9CXI5 →
P0C5H9	—	0.958	P0C5H9 →
P80513	—	0.958	P80513 →
Q49AH0	—	0.957	Q49AH0 →
P28050	—	0.956	P28050 →
P02771	—	0.956	P02771 →
GC	Vitamin D-binding protein	0.956	landscape →
O35298	—	0.956	O35298 →
Q28789	—	0.955	Q28789 →
P53789	—	0.955	P53789 →
P49066	—	0.955	P49066 →
P04276	—	0.955	P04276 →
Q8C1C1	—	0.954	Q8C1C1 →
O18823	—	0.954	O18823 →
O70367	—	0.953	O70367 →
O75829	—	0.953	O75829 →
P17404	—	0.953	P17404 →
P21614	—	0.953	P21614 →
Q8MJ76	—	0.953	Q8MJ76 →
P28039	—	0.953	P28039 →
A6YF56	—	0.953	A6YF56 →
Q6NUJ1	—	0.952	Q6NUJ1 →
Q3MHN5	—	0.952	Q3MHN5 →
Q8MJU5	—	0.952	Q8MJU5 →
P20097	—	0.952	P20097 →